GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 27
- Registration Number
- NCT04608344
- Locations
- 🇺🇸
Prism Research, LLC, Saint Paul, Minnesota, United States
Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation
- First Posted Date
- 2020-09-04
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 156
- Registration Number
- NCT04539262
- Locations
- 🇺🇸
Aurora FDRC Inc., Costa Mesa, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Research in Miami, Inc., Hialeah, Florida, United States
Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice in Participants With Metastatic or Locally Advanced Unresectable Urothelial Cancer
- Conditions
- Locally Advanced or Metastatic Unresectable Urothelial Cancer
- Interventions
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 696
- Registration Number
- NCT04527991
- Locations
- 🇺🇸
Mayo Clinic - Arizona, Phoenix, Arizona, United States
🇺🇸University of California Irvine (UCIMC), Orange, California, United States
🇺🇸MedStar Washington Hospital Center, Washington, District of Columbia, United States
Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 584
- Registration Number
- NCT04501952
- Locations
- 🇺🇸
Mills Clinical Research, Los Angeles, California, United States
🇺🇸NorthStar Medical Center, Chicago, Illinois, United States
🇺🇸University of Maryland Baltimore, Baltimore, Maryland, United States
Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 9
- Registration Number
- NCT04502706
- Locations
- 🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy
- Conditions
- Ankylosing Spondylitis
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT04483700
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy
- Conditions
- Ankylosing Spondylitis
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT04483687
Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
- Conditions
- Metastatic Triple-negative Breast Cancer
- Interventions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 80
- Registration Number
- NCT04454437
- Locations
- 🇨🇳
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
🇨🇳Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Chinese PLA General Hospital, Beijing, China
Study of Remdesivir in Participants Below 18 Years Old With COVID-19
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 59
- Registration Number
- NCT04431453
- Locations
- 🇺🇸
Johns Hopkins Children's Center, Baltimore, Maryland, United States
🇺🇸Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, United States
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)
- Conditions
- SARS-CoV2 Infection
- First Posted Date
- 2020-03-27
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT04323761
- Locations
- 🇺🇸
Charlton Memorial Hospital, Fall River, Massachusetts, United States
🇺🇸Lawrence General Hospital, Lawrence, Massachusetts, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States